<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873765</url>
  </required_header>
  <id_info>
    <org_study_id>Megalabs</org_study_id>
    <nct_id>NCT04873765</nct_id>
  </id_info>
  <brief_title>Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers</brief_title>
  <official_title>Phase I Clinical Trial With Pharmacokinetic and Pharmacodynamic Determination of Subcutaneous Pegfilgrastim in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Megalabs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Megalabs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the pharmacokinetics and pharmacodynamics, after single subcutaneous&#xD;
      application, in healthy men, between pegfilgrastim formulation, produced by Megalabs (test&#xD;
      product) and Neulastim® (reference product) Amgen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Cmax in healthy volunteers for test and reference</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of AUC 0-t of pegfilgrastim in healthy volunteers for test and reference</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of absolute neutrophil count (ANC) in healthy volunteers for test and reference</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of CD34+ count for test and reference</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>Pegfilgrastim Megalabs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegfilgrastim injectable 6 mg in a single subcutaneous application.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegfilgastrim Neulastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neulastim injectable 6 mg in a single subcutaneous application.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgastrim Megalabs</intervention_name>
    <description>Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose</description>
    <arm_group_label>Pegfilgastrim Neulastim</arm_group_label>
    <arm_group_label>Pegfilgrastim Megalabs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgastim Amgen</intervention_name>
    <description>Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose</description>
    <arm_group_label>Pegfilgastrim Neulastim</arm_group_label>
    <arm_group_label>Pegfilgrastim Megalabs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy eligible participants able to read, understand and sign the latest version of&#xD;
             the Informed Consent Form (ICF) approved by the Research Ethics Committee (CEP)&#xD;
&#xD;
          -  Males aged between 18 and 55 years&#xD;
&#xD;
          -  Be characterized as a healthy research participant, based on medical history general&#xD;
             physical examination and vital signs, laboratory tests and electrocardiogram (ECG),&#xD;
&#xD;
          -  Not indicating any evidence of disease&#xD;
&#xD;
          -  Body weight between 60-100 kg;&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 18.5 and ≤ 29.9 Kg / m2;&#xD;
&#xD;
          -  Negative test for coronavirus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Present one or more flu-like symptoms such as: fever (body temperature greater than or&#xD;
             equal to 37.8 ° C), cough, dyspnoea, myalgia and fatigue, respiratory symptoms,&#xD;
             gastrointestinal symptoms (such as diarrhea) within 7 days prior to the&#xD;
             hospitalization period (all periods);&#xD;
&#xD;
          -  Direct and significant medical contact with people who tested positive for coronavirus&#xD;
             testing within 14 days prior to the hospitalization period (all periods);&#xD;
&#xD;
          -  Living in the same household as people who are in the risk group with the worst&#xD;
             prognosis for coronavirus infection, such as individuals over 60, individuals with&#xD;
             respiratory problems, immunosuppressed or those with chronic diseases, such as heart&#xD;
             or diabetes (all periods).&#xD;
&#xD;
          -  Participants diagnosed with malignant disease in the last 5 years, with the exception&#xD;
             of successfully treated basal cell carcinoma;&#xD;
&#xD;
          -  Participants with a previous diagnosis of severe asthma, sickle cell anemia,&#xD;
             idiopathic urticaria or anaphylaxis;&#xD;
&#xD;
          -  Participants with chronic diseases and, therefore, who regularly use medications;&#xD;
&#xD;
          -  Being a smoker or quitting less than 6 months ago;&#xD;
&#xD;
          -  Participants who consume more than 5 cups of tea or coffee a day and who cannot&#xD;
             abstain during the trial period;&#xD;
&#xD;
          -  History of alcohol and illicit drug abuse&#xD;
&#xD;
          -  Electrocardiogram (ECG) findings that, at the investigator's discretion, may&#xD;
             compromise participation in the trial;&#xD;
&#xD;
          -  History or presence of gastrointestinal or liver diseases or any other condition that&#xD;
             interferes with the absorption, distribution, excretion or metabolism of the drug;&#xD;
&#xD;
          -  Use of lithium 2 weeks before and / or after medication administration;&#xD;
&#xD;
          -  Participants who are hypersensitive or contraindicated to use any of the components of&#xD;
             the formulation;&#xD;
&#xD;
          -  Research participants who have participated in clinical trial protocols in the last 12&#xD;
             (twelve) months (Resolution CNS 251, of August 7, 1997, item III, subitem J);&#xD;
&#xD;
          -  Have donated blood (&gt; 500 mL) or have undergone major surgery in the 3 (three) months&#xD;
             preceding the date of signing the informed consent form;&#xD;
&#xD;
          -  Have received any vaccine in the 3 (three) months preceding the date of signing the&#xD;
             informed consent form;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Pedrazzoli Junior, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidade Integrada de Farmacologia e Gastroenterologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcos Giusti, MD</last_name>
    <phone>+598926838000</phone>
    <phone_ext>3100</phone_ext>
    <email>mgiusti@megalabs.global</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victoria Rodríguez, MD</last_name>
    <phone>+598926838000</phone>
    <email>vrodrigez@megalabs.global</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

